Drug and vaccine access in the Ebola epidemic: Advising caution in compassionate use

Annals of Internal Medicine

Volumn 162, Issue 2, 2015, Pages 141-142

  Hantel, Andrew ^a   Olopade, Christopher Olusola ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; INFUSION FLUID; ANTIVIRUS AGENT; VACCINE;

ANIMAL MODEL; CATHETER; COMPASSIONATE USE; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HUMAN; INTENSIVE CARE; MEDICAL ETHICS; NONHUMAN; NOTE; POLICY; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; AFRICA; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; WORLD HEALTH ORGANIZATION;

AFRICA, WESTERN; ANTIVIRAL AGENTS; COMPASSIONATE USE TRIALS; EPIDEMICS; ETHICS, MEDICAL; HEMORRHAGIC FEVER, EBOLA; HUMANS; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84921686089     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-2002     Document Type: Note

References (10)

1. World Health Organization. Ethical considerations for use of unregistered interventions for Ebola viral disease: report of an advisory panel to WHO. Geneva: World Health Organization; 2014. Accessed at http://apps.who.int/iris/bitstream/10665/130997/1/WHO-HIS-KER-GHE-14.1-eng.pdf on 17 August 2014.
2. Gallagher J. Ebola: Experimental drug ZMapp is '100% effective' in animal trials. BBC News. 29 August 2014. Accessed at www.bbc.com/news/health-28980153 on 26 September 2014.
3. Gallagher J. Ebola: How bad can it get? BBC News. 5 September 2014. Accessed at www.bbc.com/news/health-29060239 on 26 September 2014.
4. U.S. Department of Health and Human Services. Guidance for Industry: Expanded Access to Investigational Drugs for Treatment Use-Qs & As. Washington, DC: U.S. Department of Health and Human Services; 2013. Accessed at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM351261.pdf on 26 September 2014.
5. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7:393-400. [PMID: 19369954] doi:10.1038/nrmicro2129.
6. Dennis B, Cha AE. 'Right to Try' laws spur debate over dying patients' access to experimental drugs. The Washington Post. 16 May 2014. Accessed at www.washingtonpost.com/national/health-science/right-to-try-laws-spur-debate-over-dying-patients-access-to-experimental-drugs/2014/05/16/820e08c8-dcfa-11e3-b745-87d39690c5c0-story.html on 26 September 2014.
7. Annas GJ. Globalized clinical trials and informed consent. N Engl J Med. 2009;360:2050-3. [PMID: 19439740] doi:10.1056/NEJMp0901474.
8. Faden RR, Beauchamp TL, Kass NE. Informed consent, comparative effectiveness, and learning health care. N Engl J Med. 2014;370: 766-8. [PMID: 24552325] doi:10.1056/NEJMhle1313674.
9. World Health Organization. Ebola situation in Liberia: nonconventional interventions needed. Geneva: World Health Organization; 2014. Accessed at www.who.int/entity/mediacentre/news/ebola/8-september-2014/en/index.htm on 26 September 2014.
10. Adebamowo C. Statement on the use of innovative or nonvalidated medical treatment in Nigeria. Abuja, Nigeria: National Health Research Ethics Committee of Nigeria, Federal Ministry of Health; 2014. Accessed at http://nhrec.net/nhrec/statement-on-the-use-of-innovative-or-non-validated-medical-treatment-in-nigeria on 26 September 2014.